History

2017

Ethypharm acquired Martindale Pharma creating its position as a leading UK-based specialty pharmaceutical company providing value adding pharmaceutical products to over 80 countries around the world. Specialising in the fields of Opioid Addiction, Critical Care and Pain, Ethypharm UK is recognised as a key partner to the NHS and the private hospital sector with a vast range of quality products.

2015

Ethypharm acquired DB Ashbourne, which became the UK subsidiary of the Group. Ethypharm UK started to market and supply its products directly including Morphine Sulfate prolonged release under the name of Zomorph®.

2009

DB Ashbourne LTD establishes in the UK as a branded pharmaceutical business, commercial operations started in 2009 with the marketing and supply of a range of prescription only medicines to the UK market and generating significant savings for the National Health Service.

1999

Ethypharm acquired Prographarm Laboratoire in France.

1977

Ethypharm established and became rapidly a major player in the field of Drug Delivery Systems in France.

1990

Martindale Pharma was launched as a trading company for Macarthys Laboratories Ltd.

1967

Savory and Moore Ltd was acquired by Macarthys Laboratories Ltd.

1933

William Martindale was acquired by Savory & Moore Ltd.

1873

William Martindale acquired a pharmacy from Hopkins & Williams.

1787

James Macarthy founded a retail pharmacy in Romford.

Ethypharm UK - part of the Ethypharm Group

By joining forces with Martindale Pharma, Ethypharm reinforced its presence in the UK and the combined group now benefits from a broader geographical reach. This allows the Group to commercialise its products into many markets helping patients around the world get access to better medicines.

The consolidation of Martindale Pharm with Ethypharm UK has enabled stronger manufacturing capabilities to be developed including solid dose, injectables and oral liquids.

By clicking on this link, you agree to leave our website.
Are you sure?

NO YES

FREQUENTLY ASKED QUESTIONS

select products

PRODUCTSREQUESTS

Abtard®

Are there bioequivalence data with OxyContin?
Yes, data from twelve bioequivalence studies comparing Abtard with the reference product were submitted in support of the application for Marketing Authorisation.
Is Abtard Monophasic or biphasic?
Abtard prolonged -release tablets are bioequivalent to OxyContin prolonged-release tablets and are biphasic, meaning that there is an initial absorption of approximately 40% of oxycodone from the tablet providing onset of analgesia within one hour in most patients, followed by a more controlled absorption, which determines the 12-hour duration or action.
How do I store Abtard® tablets?
We do not have information on the stability of Abtard® tablets outside of the original packaging. Abtard® tablets must be stored below 25°C in the original packaging to protect from moisture.
How do I take Abtard® tablets?
Abtard® tablets must be taken as directed by your doctor or pharmacist. Abtard® tablets must be swallowed whole with a sufficient amount of liquid and not chewed.
Are the tablets film coated?
Yes they are
Are 2 x 60mg tablets bioequivalent to a single 120mg strength of OxyContin?
There are no bioequivalence studies for Abtard 2 x 60mg versus one single dose of 120mg of OxyContin. It is a matter of clinical judgement for the prescriber to decide whether 2 x 60 mg tablets can be used. What the bioequivalence studies prove is that Abtard 60mg is bioequivalent to OxyContin 60mg. In practice if a retail pharmacist received a prescription for 120mg of OxyContin and only had the 60mg OxyContin available would they give 2 x 60mg tablets

DIDN'T FIND WHAT YOU WERE LOOKING FOR?
Please feel free to contact us for any further question. Please note that we are unable to provide medical advice.
Contact: medinfo@martindalepharma.co.uk

HOW MUCH COULD YOU SAVE ?

CHOOSE YOUR CCG

TOTAL CCG
SAVINGS across our products

£0.00

CHOOSE A PRACTICE NAME

TOTAL PRACTICE
SAVINGS across our products

£0.00

England & Wales
The data in this dashboard includes General Practice Prescribing Data - NHS prescriptions that are prescribed in England & Wales by GPs, and non medical prescribers that have prescribed on behalf of the GP practice, that are then dispensed in the community.

NHS Prescription Services, part of the NHS Business Services Authority (BSA), is the provider of the England data and NHS Wales Shared Partnerships Services is the provider of the Wales data.

This public sector information is licensed under the Open Government Licence v3.0.

The cost model compares Ethypharm products to alternative products. Only comparable doses of alternative products, which can be clearly identified in the NHS prescription data, are used in the model.

Scotland
The data in this dashboard includes General Practice Prescribing Data - NHS prescriptions that are prescribed in Scotland by GPs, and non medical prescribers that have prescribed on behalf of the GP practice, that are then dispensed in the community.

ISD, NHS Scotland is the provider of the data.

This public sector information is licensed under the Open Government Licence v3.0.

The cost model compares Ethypharm products to alternative products. Only comparable doses of alternative products, which can be clearly identified in the NHS prescription data, are used in the model.